Orchestra BioMed Appoints Vivek Reddy, M.D. as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory Board

Core Viewpoint - Orchestra BioMed Holdings, Inc. has appointed Dr. Vivek Reddy as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of the Bioelectronic Therapies Scientific Advisory Board to enhance the development of its bioelectronic therapies portfolio and lead the BACKBEAT global pivotal study [1][2] Company Overview - Orchestra BioMed is a biomedical innovation company focused on accelerating high-impact technologies through risk-reward sharing partnerships with leading medical device companies [3][5] - The company's lead product candidate is atrioventricular interval modulation (AVIM) therapy aimed at treating hypertension, a significant global health risk [3][5] BACKBEAT Study - The BACKBEAT global pivotal study is currently enrolling patients to assess the efficacy and safety of AVIM therapy for those with uncontrolled hypertension and a pacemaker indication [4] - The study aims to provide critical scientific evidence and clinical value for AVIM therapy, which is designed to offer an adjustable treatment option that does not depend on patient adherence [2][4] Leadership and Expertise - Dr. Vivek Reddy brings extensive experience in electrophysiology and cardiac rhythm management, currently serving in multiple leadership roles at The Mount Sinai Health System [2][4] - His leadership is expected to enhance awareness and communication regarding AVIM therapy within the clinical community, facilitating the successful completion of the BACKBEAT study [2][4]